Alpine Immune Sciences, Inc. focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer. The company has a collaboration and licensing agreement with the Kite Pharma, Inc. for discovering and developing protein-based immunotherapies targeting the immune synapse to treat cancer. Alpine Immune Sciences, Inc. is headquartered in Seattle, Washington.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ALPN
CUSIPN/A
Phone206-788-4545
Debt
Debt-to-Equity Ratio0.05
Current Ratio26.70
Quick Ratio26.71
Price-To-Earnings
Trailing P/E Ratio-6.81
Forward P/E Ratio-4.30
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.73 million
Price / Sales65.41
Cash FlowN/A
Price / CashN/A
Book Value$5.68 per share
Price / Book1.44
Profitability
EPS (Most Recent Fiscal Year)($1.20)
Net Income$-7,780,000.00
Net MarginsN/A
Return on Equity-20.70%
Return on Assets-19.05%
Miscellaneous
Employees38
Outstanding Shares13,850,000
Alpine Immune Sciences (NASDAQ:ALPN) Frequently Asked Questions
What is Alpine Immune Sciences' stock symbol?
Alpine Immune Sciences trades on the NASDAQ under the ticker symbol "ALPN."
How were Alpine Immune Sciences' earnings last quarter?
Alpine Immune Sciences Inc (NASDAQ:ALPN) posted its quarterly earnings data on Monday, May, 14th. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.40) by $0.01. The biotechnology company earned $0.32 million during the quarter, compared to analysts' expectations of $0.13 million. View Alpine Immune Sciences' Earnings History.
What price target have analysts set for ALPN?
2 brokerages have issued 12-month price objectives for Alpine Immune Sciences' stock. Their forecasts range from $13.00 to $17.00. On average, they anticipate Alpine Immune Sciences' share price to reach $15.00 in the next twelve months. View Analyst Ratings for Alpine Immune Sciences.
Who are some of Alpine Immune Sciences' key competitors?
Some companies that are related to Alpine Immune Sciences include Concert Pharmaceuticals (CNCE), ZEALAND PHARMA/S (ZEAL), Clementia Pharmaceuticals (CMTA), Cytokinetics (CYTK), Synergy Pharmaceuticals (SGYP), Mersana Therapeutics (MRSN), Dermira (DERM), GTX (GTXI), Syros Pharmaceuticals (SYRS), Achillion Pharmaceuticals (ACHN), Savara (SVRA), American Brivision (Holding) (ABVC), Albireo Pharma (ALBO), Tyme Technologies (TYME) and Bellicum Pharmaceuticals (BLCM).
Who are Alpine Immune Sciences' key executives?
Alpine Immune Sciences' management team includes the folowing people:
- Dr. Mitchell H. Gold, Exec. Chairman and Acting Chief Exec. Officer (Age 50)
- Dr. Jay R. Venkatesan M.D., Ph.D., Pres and Director (Age 46)
- Dr. Stanford Peng M.D., Ph.D., Exec. VP of R&D and Chief Medical Officer (Age 47)
- Mr. Paul Rickey, Sr. VP & CFO (Age 39)
- Mr. Ryan Swanson, Co-Founder
Has Alpine Immune Sciences been receiving favorable news coverage?
Media stories about ALPN stock have trended positive on Wednesday, according to Accern Sentiment. The research group identifies negative and positive news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Alpine Immune Sciences earned a coverage optimism score of 0.30 on Accern's scale. They also assigned news stories about the biotechnology company an impact score of 45.87 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
Who are Alpine Immune Sciences' major shareholders?
Alpine Immune Sciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Victory Capital Management Inc. (0.52%). Company insiders that own Alpine Immune Sciences stock include Bvf Partners L P/Il, David Malcom Rodman, Janice Troha, R Michael Carruthers, Robert E Conway and Value Fund L P Biotechnology. View Institutional Ownership Trends for Alpine Immune Sciences.
Which major investors are buying Alpine Immune Sciences stock?
ALPN stock was purchased by a variety of institutional investors in the last quarter, including Victory Capital Management Inc.. Company insiders that have bought Alpine Immune Sciences stock in the last two years include Bvf Partners L P/Il, Janice Troha, R Michael Carruthers, Robert E Conway and Value Fund L P Biotechnology. View Insider Buying and Selling for Alpine Immune Sciences.
How do I buy shares of Alpine Immune Sciences?
Shares of ALPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Alpine Immune Sciences' stock price today?
One share of ALPN stock can currently be purchased for approximately $8.17.
How big of a company is Alpine Immune Sciences?
Alpine Immune Sciences has a market capitalization of $114.23 million and generates $1.73 million in revenue each year. The biotechnology company earns $-7,780,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Alpine Immune Sciences employs 38 workers across the globe.
How can I contact Alpine Immune Sciences?
Alpine Immune Sciences' mailing address is 201 Elliott Avenue West Suite 230, Seattle WA, 98119. The biotechnology company can be reached via phone at 206-788-4545 or via email at [email protected]
MarketBeat Community Rating for Alpine Immune Sciences (ALPN)
MarketBeat's community ratings are surveys of what our community members think about Alpine Immune Sciences and other stocks. Vote "Outperform" if you believe ALPN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALPN will underperform the S&P 500 over the long term. You may vote once every thirty days.
